Surrozen Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $11.5M+8.0% YoYTTM through 30 Jun 2026
Net Income -$332.1MTTM through 30 Jun 2026
Free Cash Flow -$35MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -383.4% |
| Operating Margin | -385.3% |
| Net Margin | -2,885.3% |
Returns
151.9%ROE
Balance Sheet Health
Current Ratio12.14x
Cash & Equivalents$102M
Quality Metrics
Altman Z-Score-7.07
Piotroski F-Score3 / 9
FCF Margin-303.9%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $3.5M
Diluted EPS-$40.06TTMFY2025: $-32,365.00
Dividend
No dividend
Capital Allocation
Capex Intensity1.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Research and development of product candidates to selectively modulate the Wnt pathway | $3.5M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.